Your browser doesn't support javascript.
loading
Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4.
Cheung, Mui; Bao, Weike; Behm, David J; Brooks, Carl A; Bury, Michael J; Dowdell, Sarah E; Eidam, Hilary S; Fox, Ryan M; Goodman, Krista B; Holt, Dennis A; Lee, Dennis; Roethke, Theresa J; Willette, Robert N; Xu, Xiaoping; Ye, Guosen; Thorneloe, Kevin S.
Afiliación
  • Cheung M; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Bao W; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Behm DJ; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Brooks CA; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Bury MJ; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Dowdell SE; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Eidam HS; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Fox RM; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Goodman KB; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Holt DA; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Lee D; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Roethke TJ; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Willette RN; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Xu X; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Ye G; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
  • Thorneloe KS; GlaxoSmithKline, Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area, King of Prussia, Pennsylvania 19406, United States.
ACS Med Chem Lett ; 8(5): 549-554, 2017 May 11.
Article en En | MEDLINE | ID: mdl-28523109
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos